Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
Laboratory tests of diffuse large B cell lymphoma include:<ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | Laboratory tests of diffuse large B cell lymphoma include:<ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | ||
* [[Complete blood count]] (CBC) | * [[Complete blood count]] (CBC) | ||
* Blood chemistry studies | * Blood chemistry studies including LDH and Uric acid | ||
* [[Flow cytometry]] | * [[Flow cytometry]] | ||
* [[Immunohistochemistry]] | * [[Immunohistochemistry]] |
Revision as of 18:16, 11 June 2018
Diffuse large B cell lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Diffuse large B cell lymphoma laboratory tests On the Web |
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
Directions to Hospitals Treating Diffuse large B cell lymphoma |
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
DLBCL require a complete work-up includes immunophenotypic analysis, cytogenetic analysis (conventional methods and FISH), and molecular diagnostic assays.
Laboratory tests of diffuse large B cell lymphoma include:[1]
- Complete blood count (CBC)
- Blood chemistry studies including LDH and Uric acid
- Flow cytometry
- Immunohistochemistry
- Cytology (for primary CNS lymphoma only)
- Genetic testing
- Immunophenotyping BCL-2+, BCL6+/-, MYC, CD5, CD10+, CD15+, CD20+, CD22+, CD30+, CD79a+, EBNA-2+, Fox-P1+, IRF4/MUM1+, P53, LMP-1+, Surface 4 or cytoplasmic immunoglobulin (Ig) is absent
References
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov